盐酸加替沙星(Gatifloxacin)体外抗菌作用

被引：33

作者：

李家泰

刘健

王彤

朱琪

刘燕

机构：

[1] 北京大学第一临床医院临床药理研究所

来源：

中国临床药理学杂志 | 2001年 / 06期

关键词：

盐酸加替沙星; 体外抗菌作用;

D O I：

10.13699/j.cnki.1001-6821.2001.06.001

中图分类号：

R965 [实验药理学];

学科分类号：

摘要：

目的：评价盐酸加替沙星（ｇａｔｉｆｌｏｘａｃｉｎ）对临床分离的１２２２株致病菌的体外抗菌作用，并与盐酸环丙沙星、氧氟沙星、司帕沙星等进行比较。结果：盐酸加替沙星对大多数革兰阴性杆菌的ＭＩＣ９０值均低于０．５ｍｇ·Ｌ－１，抗菌作用与盐酸环丙沙星相似；对肺炎克雷伯杆菌、阴沟肠杆菌、变形杆菌、志贺菌的ＭＩＣ９０值分别为０．０６２，０．０６２，０．５，０．２５ｍｇ·Ｌ－１；盐酸加替沙星对大肠杆菌的ＭＩＣ９０值为８ｍｇ·Ｌ－１，耐药率为５８％，对盐酸环丙沙星耐药的大肠杆菌对盐酸加替沙星也耐药，存在着交叉耐药性。盐酸加替沙星对乙酸钙不动杆菌ＭＩＣ９０值为０．０６２ｍｇ·Ｌ－；铜绿假单胞和窄食黄单胞菌的ＭＩＣ９０值分别为２和１ｍｇ·Ｌ－１，与盐酸环丙沙星相同。盐酸加替沙星对革兰阳性球菌的抗菌作用比盐酸环丙沙星与氧氟沙星增强，对甲氧西林敏感的金葡菌、化脓性链球菌和肺炎链球菌ＭＩＣ９０值分别为０．１２５、０．１２５和０．５ｍｇ·Ｌ－１，与司帕沙星相同；对甲氧西林耐药的金葡菌盐酸加替沙星的ＭＩＣ９０值为４ｍｇ·Ｌ－１；对表皮葡葡菌ＭＩＣ９０值０．５ｍｇ·Ｌ－１；流感嗜血杆菌对盐酸加替沙星高度敏感，ＭＩＣ９０值为０．０１６ｍｇ·

引用

页码：403 / 409

页数：7

共 8 条

[1]

Nakashima M,Uematsu T,Kosuge K,et al.Single and multiple-dose pharmacolinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents Chemotherapy . 1995

[2]

Hosaka M,Kinoshita S,Toyama A,et al.Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Agents and Chemotherapy . 1995

[3]

Hosaka M,Yasue T,Fukuda H,et al.I n vitro and in vivo antibacterial activities of AM-1155, a new l -fluoro-8methoxy quinolone. Antimicrobial Agents and Chemotherapy . 1992

[4]

National Committee for Clinical Laboratory Standard.Performance standards for antimicrobial disk susceptibility test. . 1998

[5]

Deguchi T,Yasuda M,Nakano M,ea al.Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC. Journal of Chemotherapy . 1997

[6]

Wakabayashi F,Mitsuhashi S.In vitro antibacterial activity of AM- 1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy . 1994

[7]

Wise R,Brenwald NP,Andrews JM,et al.The activity of the methylpiperazinyl fluoroquinolone CG5501 :A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Agents and Chemotherapy . 1997

[8]

Tanaka M,Takahashi K,Saika T, et al.Development of fluoroqui- noloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology . 1998

← 1 →